CMC Biologics has entered an agreement with Daiichi Sankyo Co., Ltd. to provide process development support and manufacture of several clinical-stage antibodies for a three-year period. The two companies began work on their first joint project at CMC Biologics’ Bothell manufacturing facility. Specific terms of the agreement were not disclosed.   “CMC Biologics is delighted to partner with Daiichi Sankyo, a leader among pharmaceutical companies worldwide with a heritage of scienti...